{
    "Trade/Device Name(s)": [
        "ADVIA Chemistry Enzymatic Hemoglobin A1c (A1c_E) Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K200256",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171771"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "July 2, 2021",
    "Summary Letter Received Date": "October 14, 2020",
    "Submission Date": "June 17, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated Hemoglobin Assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Total hemoglobin"
    ],
    "Specimen Type(s)": [
        "Anticoagulated venous whole blood",
        "Hemolysate"
    ],
    "Specimen Container(s)": [
        "Dipotassium EDTA tube",
        "Lithium Heparin tube",
        "Sodium Fluoride/Disodium EDTA tube",
        "Tripotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA 1800 Clinical Chemistry System"
    ],
    "Method(s)/Technology(ies)": [
        "Quantitative enzymatic assay"
    ],
    "Methodologies": [
        "Enzymatic measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Chemistry Enzymatic Hemoglobin A1c (A1c_E) Assay, a quantitative enzymatic test for hemoglobin A1c on the ADVIA 1800 platform.",
    "Indications for Use Summary": "For quantitative determination of HbA1c in anticoagulated venous whole blood and hemolysate on ADVIA Chemistry Systems to aid in diagnosis and monitoring of long-term glucose control and identification of patients at risk for diabetes mellitus.",
    "fda_folder": "Clinical Chemistry"
}